Mindset Pharma Inc. and PharmAla Biotech Holdings Inc. announced that they have entered into an exclusive sales agreement. Under the sales agreement, PharmAla will be the exclusive global reseller of Mindset's cGMP psilocybin to appropriately licensed clinical researchers. Mindset has recently completed production of a large batch of cGMP psilocybin at the U.S. site of an international contract development and manufacturing company pursuant to the annual DEA quota on psilocybin.